Nuvectis Pharma, Inc.’s NVCT share price has dipped by 11.52%, which has investors questioning if this is right time to buy.

The histone reader ENL is frequently mutated in Wilms tumor. Here they use mouse models and spatial transcriptomic analyses to show how ENL tumor mutations disrupt nephrogenesis through distinct ...

为探究神经母细胞瘤（NB）“冷肿瘤” 表型成因，研究人员聚焦 ARID1A 与 IFNγ 信号通路，发现 ARID1A 缺失是关键，为免疫治疗提供依据。 研究背景：破解神经母细胞瘤免疫治疗困境的探索之旅 在儿科癌症的世界里，神经母细胞瘤（Neuroblastoma，NB）是一个极为棘手 ...

The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for ...

Selective ARID1B degrader program. Selectively targets and degrades ARID1B in ARID1A-mutated cancers. ARID1A is the most mutated subunit in the BAF complex and amongst the most mutated proteins in ...

Additionally, Nuvectis’ second asset, NXP800, a GCN2 activator, is in Phase 1b trials targeting ARID1a-mutated ovarian cancer. Although previous dosing regimens required adjustments due to ...